External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients

Objectives In patients with essential thrombocythemia (ET), vascular complications contribute to both morbidity and mortality. To better predict the occurrence of thrombotic events, an International Prognostic Score of thrombosis for ET (IPSET‐thrombosis) was recently developed. We hereby presented...

Full description

Saved in:
Bibliographic Details
Published in:European journal of haematology 2014-06, Vol.92 (6), p.502-509
Main Authors: Fu, Rongfeng, Xuan, Min, Lv, Cuicui, Zhang, Liyan, Li, Huiyuan, Zhang, Xian, Zhang, Donglei, Sun, Tiantian, Xue, Feng, Liu, Xiaofan, Liang, Haoyue, Zhang, Lei, Yang, Renchi
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Female
Follow-Up Studies
Humans
Incidence
Male
Middle Aged
primary thrombocythemia
Prognosis
Risk Factors
Thrombocythemia, Essential - complications
Thrombocythemia, Essential - diagnosis
Thrombocythemia, Essential - mortality
Thrombocythemia, Essential - therapy
thrombosis
Thrombosis - epidemiology
Thrombosis - etiology
Thrombosis - therapy
treatment
Young Adult
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives In patients with essential thrombocythemia (ET), vascular complications contribute to both morbidity and mortality. To better predict the occurrence of thrombotic events, an International Prognostic Score of thrombosis for ET (IPSET‐thrombosis) was recently developed. We hereby presented an external validation and analysis of this model in a large Cohort of Chinese Patients. Methods We retrospectively evaluated the characteristics and risk factors for thrombosis in 970 Chinese patients with ET and estimated the clinical implications of the IPSET‐thrombosis model. Results The median follow‐up was 49 months (range, 0–360). Chinese ET patients had similar clinical characteristics as Caucasian patients. Similar to the IPSET‐thrombosis study, our multivariate analysis revealed age >60 (HR = 1.949), previous thrombosis (HR = 2.484), JAK2V617F mutation (HR = 1.719), and cardiovascular risk factors (HR = 1.877) as independent risk factors for thrombosis. We confirmed that the above risk factors in IPSET‐thrombosis, when compared with traditional risk factors (e.g., age ≥60 and previous thrombotic events), were more predictive of thrombotic events (C‐index 0.714 vs. 0.647). Classification by IPSET‐thrombosis risk groups revealed different cumulative thrombosis‐free survival (P 
ISSN:0902-4441
1600-0609
DOI:10.1111/ejh.12275